Please use this identifier to cite or link to this item:
|Title:||Availability of reimbursable oncology medicines in European Union member states|
Azzopardi, Lilian M.
|Keywords:||Cancer -- Chemotherapy|
Antineoplastic agents -- European Union countries
Drug accessibility -- European Union countries
European Union countries -- Economic conditions
|Publisher:||University of Malta. Department of Pharmacy|
|Citation:||Cachia, A., Serracino-Inglott, A., & Azzopardi, L. M. (2015, September). Availability of reimbursable oncology medicines in European Union member states. Poster session presented at the FIP 75th World Congress of Pharmacy and Pharmaceutical Sciences, Düsseldorf, Germany.|
|Abstract:||A poster presentation regarding the availability of reimbursable oncology medicines in European Union member states. Introduction: Oncology medicines are among the costliest of all medicines. Most European Union (EU) member states make decisions to reimburse oncology medicines based on national lists of reimbursable medicines, called positive lists. Aims: ▫ To compare the availability of reimbursable oncology medicines between EU member states. ▫ To determine if a relationship exists between the amount of reimbursable oncology medicines and the member states’ economic situation.|
|Appears in Collections:||Scholarly Works - FacM&SPha|
Files in This Item:
|Availability_of_reimbursable_oncology_medicines_in_European_Union_member_states_2015.pdf||447.05 kB||Adobe PDF||View/Open|
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.